Arcturus Therapeutics Holdings Inc (NQ:ARCT)

14.66 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

70 Biggest Movers From Friday ↗

May 31, 2022

Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...

Via Benzinga

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Expert Ratings for Arcturus Therapeutics ↗

May 10, 2022

Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022 ↗

May 11, 2022

Upgrades

Via Benzinga

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

May 09, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics's Earnings Outlook ↗

May 06, 2022

Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study ↗

April 20, 2022

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial ↗

May 05, 2022

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months...

Via Benzinga

Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

May 05, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

April 27, 2022

From Arcturus Therapeutics

Via Business Wire

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 22, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

28 Stocks Moving In Wednesday's Mid-Day Session ↗

April 20, 2022

Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52...

Via Benzinga

Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points ↗

April 20, 2022

U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 250 points on Wednesday.

Via Benzinga

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study ↗

April 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 20, 2022

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 40.0% to $1.4 during Wednesday's pre-market session. The company's market cap stands at $39.8 million....

Via Benzinga

Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

April 20, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

March 25, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx ↗

March 22, 2022

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical...

Via Benzinga

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 18, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

March 14, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics's Earnings Outlook ↗

February 25, 2022

Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

February 16, 2022

From Arcturus Therapeutics

Via Business Wire

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

February 08, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

January 25, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses ↗

January 24, 2022

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying...

Via Benzinga

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

January 24, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 21, 2022

From Arcturus Therapeutics

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.